European Journal of Nuclear Medicine and Molecular Imaging

SEP 11, 2026 · JOURNAL ARTICLE

Baseline serum carcinoembryonic antigen (CEA) is an independent prognostic biomarker for metastatic castration-resistant prostate cancer (mCRPC) patients receiving 177Lu-PSMA therapy

European Journal of Nuclear Medicine and Molecular Imaging

PURPOSE: 177Lu-PSMA is currently approved for metastatic castration-resistant prostate cancer (mCRPC). However, only a subset of eligible patients derives a meaningful clinical ben

SEP 8, 2026 · JOURNAL ARTICLE

External validation of the bellmunt risk score for survival prediction in mCRPC patients undergoing [177Lu]Lu-PSMA-617 therapy

European Journal of Nuclear Medicine and Molecular Imaging

External validation of an established prognostic score in an independent cohort, demonstrating reproducibility of risk stratification and survival prediction with robust performance metrics, but not introducing new clinical intervention or changing treatment selection.

SEP 8, 2026 · JOURNAL ARTICLE

Organ and tumor dosimetry of [161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC

European Journal of Nuclear Medicine and Molecular Imaging

First dosimetry characterization of 161Tb-PSMA-617 in a small, uncontrolled registry cohort without clinical outcome data, providing absorbed dose estimates but lacking efficacy, safety or comparative evidence.